Letter to the Editor: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?
Abstract
HepatologyVolume 72, Issue 4 p. 1497-1498 Correspondence Letter to the Editor: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment? Jiezhong Chen Ph.D., Jiezhong Chen Ph.D. Medlab Clinical, Sydney, NSW, AustraliaSearch for more papers by this authorLuis Vitetta Ph.D., Luis Vitetta Ph.D. Medlab Clinical, Sydney, NSW, Australia Faculty of Medicine and Health, University of...
Paper Details
Title
Letter to the Editor: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?
Published Date
Oct 1, 2020
Journal
Volume
72
Issue
4
Pages
1497 - 1498
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History